#### 1 <u>Title:</u> Head-to-head comparison of diagnostic accuracy of TB screening tests: Chest-X-2 ray, Xpert TB host response, and C-reactive protein

- 3
- 4 <u>Authors</u>: Rebecca Crowder<sup>1</sup>, Balamugesh Thangakunam<sup>2</sup>, Alfred Andama<sup>3</sup>, Devasahayam J
- 5 Christopher<sup>2</sup>, Victoria Dalay<sup>4</sup>, Welile Dube-Nwamba<sup>5</sup>, Sandra V. Kik<sup>6</sup>, Dong Van Nguyen<sup>7</sup>,
- 6 Nguyen Viet Nhung<sup>8</sup>, Patrick PJ Phillips<sup>1</sup>, Morten Ruhwald<sup>6</sup>, Grant Theron<sup>5</sup>, William
- 7 Worodria<sup>3</sup>, Charles Yu<sup>4</sup>, Payam Nahid<sup>1</sup>, Adithya Cattamanchi<sup>9</sup>, Ankur Gupta-Wright<sup>10-11</sup>,
- 8 Claudia M. Denkinger<sup>10,12</sup> for the R2D2 TB Network
- 9
- 10 1. Center for Tuberculosis and Division of Pulmonary and Critical Care Medicine, University
- 11 of California San Francisco, San Francisco, USA.
- 12 2. Christian Medical College, Vellore, India.
- 13 3. Makerere University, Kampala, Uganda.
- 14 4. De la Salle Medical and Health Sciences Institute, Dasmariñas, Philippines.
- 15 5. Stellenbosch University, Cape Town, South Africa.
- 16 6. FIND, Geneva, Switzerland.
- 17 7. Hanoi Lung Hospital, Hanoi, Vietnam.
- 18 8. Vietnam National Lung Hospital, NTP, HMU, Hanoi, Vietnam.
- 19 9. Division of Pulmonary Diseases and Critical Care Medicine, University of California
- 20 Irvine, Irvine, CA.
- 21 10. Division of Infectious Disease and Tropical Medicine, University Hospital of Heidelberg,
- 22 Heidelberg, Germany.
- 23 11. Department of Infectious Diseases, Imperial College London, UK.
- 24 12. German Center of Infection Research, partner site Heidelberg, Germany.
- 25
- 26 Corresponding author:
- 27 Claudia Denkinger
- 28 <u>Claudia.Denkinger@uni-heidelberg.de</u>
- 29
- 30 Abstract: 321
- 31 Word count: 3,092
- 32 Tables and figures: 5
- 33

#### 1 ABSTRACT 2

Background: Accessible, accurate screening tests are necessary to advance tuberculosis (TB)
 case finding and early detection in high-burden countries. We compared the diagnostic
 accuracy of available TB triage tests.

6

7 **Methods:** We prospectively screened consecutive adults with  $\geq 2$  weeks of cough presenting 8 to primary health centers in the Philippines, Vietnam, South Africa, Uganda, and India. All 9 participants received the index tests: chest-X-ray (CXR), venous or capillary Cepheid Xpert 10 TB Host Response (HR) testing, and point-of-care C-reactive protein (CRP) testing (Boditech iChroma II). CXR images were processed using computer-aided detection (CAD) algorithms. 11 12 We assessed diagnostic accuracy against a microbiologic reference standard (sputum Xpert 13 Ultra, culture). Optimal cut-points were chosen to achieve sensitivity  $\geq 90\%$  and maximize 14 specificity. Two-test screening algorithms were considered, using two approaches: 1) 15 sequential negative serial screening in which the second screening test is conducted only if the 16 first is negative and positive is defined as positive on either test and 2) sequential positive serial 17 screening, in which the second screening test is conducted only if the first is positive and 18 positive is defined as positive on both tests.

19

20 Results: Between July 2021 and August 2022, 1,392 participants with presumptive TB had 21 valid results on index tests and the reference standard, and 303 (22%) had confirmed TB. In 22 head-to-head comparisons, CAD4TB v7 showed the highest specificity when using a cut-point 23 that achieves 90% sensitivity (70.3% vs. 65.1% for Xpert HR, difference 95% CI 1.6 to 8.9; 24 49.7% for CRP, difference 95% CI 17.0 to 24.3). Among the possible two-test screening 25 algorithms, three met WHO target product profile (TPP) minimum accuracy thresholds and 26 had higher accuracy than any test alone. At 90% sensitivity, the specificity was 79.6% for Xpert 27 HR-CAD4TB [sequential negative], 75.9% for CRP-CAD4TB [sequential negative], and 28 73.7% for Xpert HR-CAD4TB [sequential positive].

29

Conclusions: CAD4TB achieves TPP targets and outperforms Xpert HR and CRP. Combining
 screening tests further increased accuracy. Cost and feasibility of two-test screening algorithms
 should be explored.

- 33
- 34 Registration: NCT04923958

## 1 INTRODUCTION

Approximately 7.5 million people were diagnosed with Tuberculosis (TB) in 2022 and 1.3 million people died from the disease [1]. Globally, 3.1 million TB cases were undiagnosed or unreported in 2022 [1]. This demonstrates that access to high-quality and affordable TB testing remains limited, making TB diagnosis the weakest link in the TB cascade of care. World Health Organization (WHO) target product profiles (TPPs) for TB diagnostics prioritize a simple, lowcost, non-sputum-based point-of-care (POC) triage or screening test to rule-out TB and guide confirmatory testing [2].

9

10 Promising TB triage tests include improvements on established technologies, such as chest Xray (CXR); new application of existing tests, such as C-reactive protein (CRP); and novel 11 12 assays, including the Xpert TB Host Response (Xpert HR) cartridge (Cepheid, Sunnyvale, 13 USA). CXR implementation for TB screening has been limited in resource-constrained settings 14 due to centralized CXR infrastructure [3] and scarcity of skilled personnel for interpretation 15 [4]. The advent of digital CXR with computer-aided detection (CAD) analysis may reduce 16 barriers to CXR screening by quickly enabling screening without the need for a skilled reader 17 [5, 6]. However, performance varies by population screened, and limited data are available for 18 children [7-10]. CRP is a non-specific marker for inflammation that has shown better accuracy 19 than symptom screening for TB among people living with HIV (PLHIV) [11]. High CRP levels 20 correlate with mycobacterial load and are associated with poor prognostic clinical features and 21 a higher risk of death [12, 13]; however, CRP alone has not been shown to meet TPP specificity 22 targets [11, 12, 14]. The recently developed Xpert HR assay detects expression levels of three 23 host genes in whole blood. Results from early studies found that this assay approaches WHO 24 minimum accuracy targets for a non-sputum-based triage test [15, 16].

25

Direct comparison of diagnostic accuracy, alongside comparisons of cost and operational characteristics, are needed to guide policy decisions around the implementation of novel TB screening tests and assess consistency with TPP targets. Testing algorithms that combine available tests may be needed to meet desired characteristics. CXR combined with CAD as a second screening test is considered a possible option by WHO. We aimed to conduct a headto-head comparison of the diagnostic accuracy of three potential TB screening tests, including CAD, CRP, and Xpert HR in a large multi-country cohort of people with presumptive TB.

33

## 34 METHODS

35

36 Study design, population, and procedures. In this prospective study, we screened adults ( $\geq 18$ 37 years) presenting to primary health centers with presumed TB between July 2021 and August 38 2022 in the Philippines, Vietnam, Uganda, South Africa, and India. Specific enrollment 39 locations have been reported previously [16] and are listed in the Appendix (Appendix Table 40 S1). We enrolled consecutive outpatients if they had  $\geq 2$  weeks of new or worsening cough. We 41 excluded people who had completed treatment for TB infection or disease within the past 12 42 months, had taken antibiotics with anti-mycobacterial activity within 2 weeks of study entry, 43 or were unable or unwilling to return for follow-up or provide informed consent. All 44 participants had HIV and diabetes screening (using HbA1c), and 2-3 spot sputum samples were 45 collected for reference standard testing (sputum was induced if unable to expectorate 46 spontaneously). Study participants received CXR, provided venous or capillary blood for Xpert HR testing, and provided capillary blood for CRP testing. 47

48

Index testing. All participants underwent antero-posterior or postero-anterior CXR at baseline.
 If digital CXR was not available, analog CXR images were scanned to create jpeg images which

1 were then converted into DICOM format using the img2dcm tool from the dcmtk toolkit 2 (v3.6.6). Images that did not fulfill the DICOM features that were required for successful CAD 3 software processing were subsequently modified using the dcmodify tool (v3.6.6) from the 4 dcmtk toolkit before they were processed with the CAD software. Images were processed using 5 five different CAD algorithms, but based on previous analysis [17], we chose the best 6 performing CAD algorithm, CAD4TB v7, (CAD4TB), to be evaluated for comparisons in this 7 analysis. CAD analysis was conducted by FIND, according to the developers' instructions. 8 CAD4TB produces a TB score, ranging from 0 to 100.

9

10 The Xpert® MTB-HR Research-Use-Only (RUO) prototype cartridge evaluates mRNA levels 11 of four differentially expressed genes (GBP5, DUSP3, KLF2 and TBP). Testing involved 12 inoculating the cartridge by transferring 100  $\mu$ L of freshly collected whole or capillary blood 13 in an EDTA tube into the cartridge chamber and analyzing using the GeneXpert instrument as 14 per manufacturer instructions. We calculated the 'TB score' using the formula (Ct GBP5 + Ct 15 DUSP3)/2 – Ct TBP as previously described [16].

16

17 CRP concentrations were measured at baseline from capillary blood using a United States Food 18 and Drug Administration-approved standard sensitivity POC assay, measured using ichroma II 19 (Boditech Med Inc., Chuncheon-si, South Korea) that provides quantitative results in three 20 minutes (range: 2.5-300 mg/L). A fixed-volume micropipette (50  $\mu$ L) was used to obtain and

transfer capillary blood to a reagent tube, mixed, and two drops were applied on the lateralflow device for testing.

22

No pre-specified cut-point was provided for any index test. All operators performing the index
 and reference tests were blinded to clinical details and other TB testing results.

26

27 Reference standard testing. Each participant provided 2-3 sputum samples, and the 28 microbiologic reference standard (MRS) was determined by results from sputum Xpert Ultra 29 MTB/RIF (Cepheid, Sunnyvale, USA) and mycobacterial culture (MGIT, Becton Dickinson, 30 USA; solid culture in 7h10 media was used when MGIT supplies were not available). A 31 positive reference standard was defined as a positive sputum Xpert Ultra result (grade 'very 32 low' or higher, or two 'trace' results) or a positive culture. Participants with a positive Xpert 33 Ultra result did not undergo confirmatory culture. A negative reference standard was defined 34 as no positive results on Xpert Ultra or culture and two negative cultures. Those not meeting 35 the criteria for positive or negative were defined as indeterminate and excluded from the 36 analysis.

37

In addition, we used a secondary, simplified sputum Xpert Ultra reference standard given that
 a molecular test is typically the only confirmatory TB test available in programmatic settings.

41 Statistical Analysis. For each index test, we conducted receiver operating characteristic (ROC) 42 analysis to compute the area under the curve (AUC) with 95% confidence interval (CI). 43 Participants with indeterminate index test results were excluded from the analysis. For the 44 primary analysis, optimal cut-points were chosen for each test that would achieve the TPP 45 target sensitivity  $\geq$ 90% and maximize specificity in the overall population. Two-test screening 46 algorithms were also considered. We considered 1) a sequential negative serial screening 47 approach [18], in which the second screening test is conducted only if the first is negative and 48 a positive screen is defined as positive on either test and 2) a sequential positive serial screening 49 approach [18], in which the second screening test is conducted only if the first is positive and 50 a positive screen is defined as positive on both tests (Appendix Figure S1). We considered

1 CRP and Xpert HR the more likely initial test, followed by the CAD, given the infrastructure 2 requirements necessary for CXR and CAD. For each potential combination, we considered 3 1,000 possible combinations of cut-points (100 possible cut-points for the first test and 100 4 possible cut-points for the second test). We then identified all pairs of cut-points that would 5 achieve sensitivity  $\geq 90\%$  and specificity  $\geq 70\%$ , then likewise selected the pair that achieved 6 the highest possible specificity within these constraints. With all binary tests set to have a 7 sensitivity of 90%, our primary analysis compared the specificity of each index alone and the 8 possible combined two-test screening algorithms among the entire study population. The 9 absolute difference in specificity for each pairwise comparison was calculated using 10 McNemar's test for paired proportions. Results are reported following STARD guidance [19]. Secondary analyses compared the sensitivity and specificity of the index tests alone and in 11 12 combination among subgroups of interest (by country, HIV status, diabetes status). A sample 13 size of 1,500 (300 per country) was pre-specified to achieve reasonable confidence interval 14 widths between 5.2-9.4% depending on observed test sensitivity (80-95%) and 4.6%-5.6% 15 depending on observed test specificity (60-80%) when assuming a TB prevalence of 20%. Stata 16 version 18 was used for all analyses.

17

18 Ethics. This study was registered with ClinicalTrials.gov (NCT04923958). Study procedures

19 were approved by the institutional review board (IRB) of the University of California San

Francisco, the University of Heidelberg, and by local IRBs at each enrollment site (Appendix
Table S1).

22

Funding. This work was supported by the United States National Institute of Allergy and Infectious Diseases [U01AI152087]. POC CRP test kits and ichroma II machines were donated by Boditech Med Inc, and Xpert HR test kits were donated by Cepheid. CAD was performed by FIND at no cost to the study. The installation and use of the CAD4TB software evaluated in this manuscript was provided free of charge by Delft Imaging to FIND. Study funders and product developers had no role in study design, data collection, data analysis, data interpretation, or writing.

30

# 31 **RESULTS**

32

33 Participants. Between July 2021 and August 2022, 2,046 adults were screened across clinical 34 sites in five countries (the Philippines, Vietnam, Uganda, South Africa, and India). 1,666 (81%) 35 met the criteria for inclusion in the study, of which 1,561 (94%) received all three tests. 31 36 (2%) CAD4TB readings, 27 (2%) Xpert HR results, and no CRP results were indeterminate or 37 invalid. 1,392 (89%) participants had all three index tests and the microbiologic reference 38 standard performed with valid results (Figure 1). Of the 1,392 assessable participants, 46% 39 were female, the median age was 43, 14% were living with HIV (median CD4 count 378), and 40 14% were living with diabetes (median HbA1c 7.0) (Table 1). In total, 303 (22%) had 41 microbiologically confirmed TB. However, characteristics varied by country (Table 1), with 42 TB prevalence ranging from 9% in India and the Philippines to 38% in Vietnam.

43

44 Xpert HR was conducted using venous (82%, n=1,143) or capillary blood (18%, n=249). CXR

45 images were collected digitally for 1,148 (83%), and analog images were scanned for 244

46 (18%). The distribution of each novel test quantitative result by microbiologic reference

- 47 standard category is presented in the Appendix (Appendix Table S2). There were no adverse
- 48 events from any testing.
- 49

1 The AUC for CAD4TB was 0.90 (95% CI 0.87, 0.92). Xpert HR had a similar AUC: 0.89 (95% 2 CI 0.86, 0.91), and CRP only reached 0.81 (95% CI 0.79, 0.84) (Figure 2). ROC analysis 3 against the sputum Xpert reference standard is available in the Appendix (Figure S2)

against the sputum Xpert reference standard is available in the Appendix (Figure S2).

Against the microbiologic reference standard and at a sensitivity of 90%, CAD4TB (TB score  $\geq 28.61$ ) achieved the highest specificity 70.3% (95% CI 67.5, 73.0), and Xpert HR (TB score  $\leq -1.3$ ) achieved a specificity of 65.1% (95% CI 62.2, 67.9). CRP with a cut-off of  $\geq 2.81$  mg/L achieved a specificity of 49.7% (95% CI 46.7, 52.7). At the WHO-recommended cut-point of  $\geq 5$ mg/L, sensitivity of CRP was 82.8% (95% CI 78.1, 86.9) and specificity 64.8% (95% CI 10 61.9, 67.7).

11

Evaluating CAD4TB, Xpert HR, and CRP in comparison using these cut-points, CAD4TB performs best, with a specificity of 5.2% (95% CI 1.6, 8.9) greater than Xpert HR, and 20.6% (95% CI 17.0, 24.3) greater than CRP (**Table 2**). Accuracy against the sputum Xpert Ultra alone is presented in the Appendix (**Table S6**).

16

17 Two-test screening algorithms. We found that 417 pairs of cut points for a combined Xpert 18 HR- CAD4TB test achieved TPP targets when using a sequential negative serial screening 19 approach, and 31 pairs of cut points achieved TPP targets using a sequential positive serial 20 screening approach (Figure 3). The selection process for other two-test screening algorithms 21 is presented in the Appendix (Figure S3-S4). The optimal combination of CAD4TB and Xpert 22 HR (cut-point for CAD4TB ≥49.68 and Xpert HR ≤-2.07) achieved a specificity of 79.6% 23 (95% CI 77.1, 82.0) with a sensitivity of 90%. This represents a 9.3% (95% CI 6.6, 11.9) 24 improvement over CAD4TB alone, 14.5% improvement over Xpert HR alone (95% CI 11.4, 25 17.6), and 29.9% over CRP alone (95% CI 26.5, 33.4; Table 2). Other two-step screening 26 algorithms had lower accuracy. Using sequential negative serial screening, both Xpert HR-27 CAD4TB and CRP- CAD4TB met current TPP targets. Using sequential positive serial 28 screening, only Xpert HR- CAD4TB met the current TPP targets (Table 2). The agreement 29 between tests and test algorithms is reported in the Appendix (Table S7).

30

31 Subgroup analyses. Using the same cut-points for the best-performing two-test screening 32 algorithm (Xpert HR-CAD4TB using sequential negative serial screening), accuracy varied 33 most notably by country, with sensitivity ranging from 62.1% (95% CI 42.3, 79.3) in the 34 Philippines to 100% (95% CI 85.2, 100) in India. Sensitivity was similar among people with 35 and without HIV (89.5% vs. 90.2%) and people with and without diabetes (sensitivity 91.7% 36 vs. 89.7%); specificity was similar among people with and without diabetes (77.2% vs. 80.0%) 37 and slightly higher among people without HIV (81.1% vs. 71.1% among PLHIV; Appendix 38 Figure S5). Females had lower sensitivity (81.4% vs. 94.2% among males), but higher 39 specificity (85.4% vs. 74.0%, Appendix Figure S5). Subgroup analyses of other combined 40 tests are presented in the Appendix (Figures S6-S8).

41

42 Using subgroup-specific cut-points, all one- and two-step screening algorithms except CRP 43 alone were able to achieve 90% sensitivity among participants in the Philippines (n/N=29/32644 with MRS-positive TB) and among females (n/N=95/623 with MRS-positive TB). No 45 screening algorithms met TPP targets among females, and only one screening algorithm, 46 defined by Xpert HR $\leq$ -0.658 and CAD4TB $\geq$ 6.727 met TPP targets among participants in the 47 Philippines, with a specificity >70% (**Appendix Table S3**).

48

49 In a hypothetical cohort of 1,000 people with presumed TB, assuming a TB prevalence of 10%,

50 the best-performing combined test would achieve a positive predictive value of 32.8% (95%

- 1 CI 27.3, 38.8) and a negative predictive value of 98.6% (95% CI 97.5, 99.3) (Appendix Table 2 S4). Performing CAD4TB-Xpert HR using sequential negative serial screening (positive 3 defined as CAD4TB  $\geq$ 49.68 or Xpert HR  $\leq$ -2.07), followed by sputum testing if positive, would 4 avert 726 sputum tests vs. 643 sputum tests averted if using CAD4TB alone (Appendix Table 5 S5). Both screening strategies would miss 10 (10%) people with TB. However, to achieve this 6 accuracy, performing CAD4TB-Xpert HR using sequential negative serial screening would 7 require 73-77% of participants to receive a second screening test depending on order 8 (Appendix Table S5). 9
  - 2,046 adults (≥18 years) with unexplained cough 380 (18.6%) excluded ≥2 weeks screened Treated for TB disease in last year (n=80) • Treated for TB infection in last year (n=16) Took medication with antimycobacterial activity in last 2 weeks (n=57) Lives ≥20km away from clinic or not willing to return for follow-up (n=161) Did not consent (n=61) • Later found to be ineligible (n=2) 1,666 (81.4%) participants eligible for X-ray, • Withdrew consent (n=3) Xpert-HR, and CRP testing 105 (6.3%) not tested with all X-ray not performed (n=74) • X-ray not available for CAD analysis (n=18) No tested by Xpert-HR (n=10) Not tested for CRP (n=3) 1,561 (93.7%) participants tested with Xpert-HR, CRP. CAD algorithms 175 (11.3%) missing valid index test result or microbiologic reference standard CAD4TB score not output (n=31) • Invalid CRP result (n=0) • Two invalid Xpert HR results (n=3) • One invalid Xpert HR result, test not repeated (n=24) • Indeterminate reference standard results (n=110) • Culture results not available (n=1) 1,392 (89.2%) participants with valid Xpert HR, CRP, CAD results and microbiologic reference standard results 303 (21.8%) with TB 1,089 (78.2%) without TB Sputum Xpert Ultra-positive (n=274) • Sputum Xpert Ultra-negative, culture MGIT culture-positive (n=27) negative (n=1,086) Solid culture positive (n=2) Sputum Xpert Ultra-indeterminate, culture negative (n=3)
- 10
- Figure 1. Study population. Note. Culture is not performed for participants with positive
- 12 results on sputum Xpert Ultra.

	Total	Philippines	Vietnam	Uganda	South Africa	India
	(N=1,392)	(N=326)	(N=276)	(N=267)	(N=262)	(N=261)
Age, mean $\pm$ SD (years)	$43\pm16$	$40 \pm 15$	$51\pm16$	$34\pm12$	$40\pm12$	$48\pm16$
Female	633 (45%)	181 (56%)	108 (39%)	112 (42%)	125 (48%)	107 (41%)
Body mass index (BMI), mean $\pm$ SD	$23\pm5$	$24 \pm 5$	$20\pm3$	$22\pm4$	$24\pm7$	$23\pm 6$
Person living with HIV	197 (14%)	3 (1%)	2 (1%)	80 (30%)	102 (40%)	10 (4%)
CD4 count, median (IQR)	378 (210-651)	527 (184-812)	547 (497-597)	360 (222-634)	335 (204-660)	587 (220-692)
Person living with diabetes	196 (14%)	42 (13%)	65 (24%)	25 (9%)	17 (6%)	47 (18%)
Prior TB diagnosis	271 (19%)	43 (13%)	58 (21%)	32 (12%)	100 (38%)	38 (15%)
Symptoms						
Cough ≥2 weeks	1392 (100%)	326 (100%)	276 (100%)	267 (100%)	262 (100%)	261 (100%)
Fever	489 (35%)	50 (15%)	98 (36%)	184 (69%)	93 (35%)	64 (25%)
Hemoptysis	170 (12%)	23 (7%)	61 (22%)	44 (16%)	19 (7%)	23 (9%)
Night sweats	474 (34%)	56 (17%)	89 (32%)	167 (63%)	136 (52%)	26 (10%)
Weight loss	639 (46%)	91 (28%)	79 (29%)	187 (70%)	168 (64%)	114 (44%)
Loss of appetite	515 (37%)	75 (23%)	73 (26%)	157 (59%)	114 (44%)	96 (37%)
Reference standards						
Sputum Xpert Ultra Reference Standard						
TB Negative	1114 (80%)	304 (93%)	183 (66%)	176 (66%)	213 (81%)	238 (91%)
TB Positive	274 (20%)	22 (7%)	93 (34%)	90 (34%)	47 (18%)	22 (8%)
Indeterminate	4 (0%)	0 (0%)	0 (0%)	1 (0%)	2 (1%)	1 (0%)
Highest semiquantitative grade						
Trace	6 (2%)	1 (5%)	0 (0%)	3 (3%)	2 (4%)	0 (0%)
Very low	43 (16%)	5 (23%)	14 (15%)	10 (11%)	10 (20%)	4 (18%)
Low	85 (31%)	8 (36%)	37 (40%)	19 (21%)	12 (24%)	9 (41%)
Medium	68 (25%)	6 (27%)	21 (23%)	23 (25%)	12 (24%)	6 (27%)
High	75 (27%)	2 (9%)	21 (23%)	36 (40%)	13 (27%)	3 (14%)
Microbiologic reference standard						
TB Negative	1089 (78%)	297 (91%)	171 (62%)	174 (65%)	209 (80%)	238 (91%)

\_\_\_\_\_

Table 1. Demographic and clinical characteristics by country

TB Positive	303 (22%)	29 (9%)	105 (38%)	93 (35%)	53 (20%)	23 (9%)
Sample collection						
Blood collection method						
Venous	1143 (82%)	326 (100%)	276 (100%)	267 (100%)	13 (5%)	261 (100%)
Capillary	249 (18%)	0 (0%)	0 (0%)	0 (0%)	249 (95%)	0 (0%)
CXR type						
Digital	1148 (82%)	326 (100%)	276 (100%)	23 (9%)	262 (100%)	261 (100%)
Analog	244 (18%)	0 (0%)	0 (0%)	244 (91%)	0 (0%)	0 (0%)

Missing HIV-status for 6 participants in South Africa.



Figure 2. Receiver operating characteristic curve. ROC curves against the microbiologic reference standard with AUC and 95% CI displayed for CAD4TB, Xpert HR, and CRP. The upper-left area shaded in gray notes the region where tests meet TPP targets ( $\geq$ 90% sensitivity,  $\geq$ 70% specificity). N=1,392 participants from the Philippines, Vietnam, Uganda, South Africa, and India with presumptive TB (n=303, 22% with microbiologically confirmed TB).

Table 2. Head-to-head comparison of diagnostic accuracy at primary cut-points. Cutpoints were chosen to achieve  $\geq$ 90% sensitivity and maximize specificity against the microbiologic reference standard in the overall study population.

	Quantitative value	Specificity	Absolute difference in specificity (95% CI)					
	indicating positive test	(95% CI)	vs. CAD4TB	vs. Xpert HR	vs. CRP			
One-step screening								
CAD4TB*	TB score ≥28.61	70.3% (67.5, 73.0%)	-	5.2% (1.6, 8.9)	20.6% (17.0, 24.3)			
Xpert HR	TB score ≤-1.3	65.1% (62.2, 67.9)	-5.2% (-8.9, -1.6)	-	15.4% (11.9, 19.0)			
CRP	≥2.81 mg/L	49.7% (46.7, 52.7)	-20.6% (-24.3, -17.0)	-15.4% (-19.0, -11.9)	-			
Two-step screening using sequential negative serial screening								
Xpert HR- CAD4TB*	CAD ≥49.68 or Xpert HR ≤-2.07	79.6% (77.1, 82.0)	9.3% (6.6, 11.9)	14.5% (11.4, 17.6)	29.9% (26.5, 33.4)			
CRP- CAD4TB *	CRP ≥51.38 mg/L or CAD ≥37.77	75.9% (73.3, 78.5)	5.6% (3.7, 7.5)	10.8% (7.4, 14.3)	26.3% (22.8, 29.7)			
CRP-Xpert HR	CRP≥ 66.66 or Xpert HR≤-1.34	64.2% (61.3, 67.0)	-6.2% (-9.7, -2.6)	-0.9% (-2.0, -0.2)	14.5% (11.1, 17.9)			
Two-step screening using sequential positive serial screening								
Xpert HR-CAD4TB*	Xpert HR≤-0.81 and CAD≥24.87	73.7% (71.0, 76.3)	3.4% (1.5, 5.3)	8.6% (5.4, 11.9)	24.1% (20.6, 27.5)			
CRP-CAD4TB	CRP has no added value	-	_	-	-			
CRP-Xpert HR	CRP has no added value	-	-	-	-			

CI: confidence interval; CAD: computer aided detection, represented by CAD4TB; CRP: C-reactive protein; HR: host response; TPP: target product profile

Note. The order of tests in two-step screening does not impact the accuracy.

\* Meets current TPP target ( $\geq$ 90% sensitivity,  $\geq$ 70% specificity)



Figure 3. Selection of cut points for two-step screening algorithm combining Xpert HR and CAD4TB. Panel (A) shows the possible cut-points using sequential negative serial screening, in which the second screening test is conducted only if the first is negative and a positive screen is defined as positive on either test. Panel (B) shows the possible cut-points using sequential positive serial screening, in which the second screening test is conducted only if the first is conducted only if the first is positive and a positive screen is defined as positive on both tests. The x-axis shows all potential cut-points for Xpert HR (test positive defined as less than or equal to the cut point chosen), and the y-axis shows all potential cut points for CAD4TB (test positive defined as greater than or equal to the cut point chosen). Each point on the graph corresponds to a pair of cut points used to define a positive screening algorithm. The colors represent the range of sensitivities and specificities possible. The outlined region contains pairs with sensitivity $\geq$ 90% and specificity  $\geq$ 70% (n=417 in panel A, n=31 in panel B).

#### DISCUSSION

Comparing CAD4TB, Xpert HR, and CRP, we found that CAD4TBwas the most accurate TB triage test for pulmonary TB and the only test that met WHO TPP specificity targets ( $\geq$ 70% at  $\geq$ 90% sensitivity) in a multi-country cohort of people with presumptive TB. Combining CAD4TB with Xpert HR or CRP using a sequential negative serial screening algorithm further improved accuracy, while only a combination with Xpert HR improved performance when using sequential positive serial screening. There was some variability in performance by subgroup; therefore, subgroup-specific cut-points may be warranted for best performance with implementation.

The diagnostic accuracy of CAD4TB in combination with other screening tests has not been well-studied, given the cost and infrastructure needs for CAD4TB alone are substantial. Nevertheless, per-screen costs of certain CAD solutions, when used at scale, have proven to be less costly compared with a radiologist [20] and more effective in terms of timeliness and completeness of results when implemented in a PLHIV population [21].

In a hypothetical cohort of 1,000 people with 10% TB prevalence, adding Xpert HR to CAD4TB using sequential negative serial screening averted 83 additional Xpert Ultra tests compared to using CAD4TB alone (274 vs. 357 requiring sputum Xpert testing); however, about three-quarters would require two screening tests prior to sputum testing (235 X-rays and CAD averted compared to CAD4TB alone). A sequential positive serial screening algorithm using the same tests would avert 288 X-rays compared to CAD4TB alone but require more confirmatory sputum testing (327 requiring sputum Xpert testing). Cost, however, is likely to be a major limitation of the implementation of a CAD4TB-Xpert HR screening approach, given that recent data showed the Xpert HR cartridge is unlikely to achieve cost-effectiveness if implemented alone [22]. While CRP-CAD would result in slightly decreased specificity using a sequential negative serial screening (3.7% less than Xpert HR-CAD4TB), it would avert 149 CAD4TB/CXR and 693 Xpert Ultra and thus warrants consideration from an economic standpoint. An analysis for Uganda of a CRP-CAD4TB algorithm suggested it could be cost-effective [23].

Beyond cost, uptake of this intervention may be limited by access to the equipment needed (X-ray systems, GeneXpert instrument), especially at lower-level health facilities. Furthermore, the time it takes to complete screening using both screening tests may also reduce the effectiveness of this algorithm. A more cost-efficient two-stage screening algorithm would wait until the first test result (e.g., CRP or Xpert HR) comes back before running the second test (e.g., CAD4TB). This two-step approach is considered currently by the WHO in the revision of the TPP for TB screening. However, the added steps may further delay diagnosis or result in loss to follow-up, and this needs to be further studied with implementation [23].

We found that performance varied by country and sex could be mitigated by using subgroupspecific cut-points for test positivity. Tailoring guidelines for use will be important, as using universal cut-points may miss key subgroups. However, at the same time, different cut-offs might increase the complexity of validation for policy purposes and implementation.

Strengths of this study include its population: a large, well-characterized, diverse cohort of adults with presumptive TB across five countries. Prospective and concurrent evaluation of multiple TB triage tests allowed for a head-to-head comparison of these tests. This study is methodologically robust, with consistent implementation across sites and a thorough microbiological reference standard. However, several limitations should be considered in the

interpretation of these findings: (1) The prevalence of TB differed across study sites, ranging from 9-38%, which may also suggest differing states of TB disease at the time of presentation across sites, which may explain at least some heterogeneity across sites; (2) limited generalizability beyond pulmonary TB; these results apply only to symptomatic pulmonary TB, and performance may differ in people unable to provide sputum and those with extrapulmonary TB.

In conclusion, current versions of CAD4TB achieve TPP targets for a TB triage test and outperform Xpert HR and CRP. Combining screening tests in algorithms further increases accuracy, but cost and implementation feasibility of these screening approaches will need to be evaluated.

**Author contributions:** PN, AC, and CMD conceptualized the study. RC, PPJP, AC, AGW, and CMD designed the model framework. BT, VD, WD, AA, DVN, WW, CY, NVN, GT, and DJC collected the data. RC curated the data. RC, PPJP, and AGW conducted formal analysis. RC and PPJP visualized the data. RC, BT, WD, AA, AGW, and CMD drafted the manuscript. All authors edited and approved the manuscript.

## References

- 1. World Health Organization. Global Tuberculosis Report. Geneva, Switzerland, **2023** 7 November 2023.
- 2. WHO. High priority target product profiles for new tuberculosis diagnostics: report of a consensus meeting, 28-29 April 2014, Geneva, Switzerland. Geneva: World Health Organization, **2014** 2014.
- Nathavitharana RR, Yoon C, MacPherson P, et al. Guidance for studies evaluating the accuracy of tuberculosis triage tests. The Journal of infectious diseases 2019; 220(Supplement\_3): S116-S25.
- Kik SV, Gelaw SM, Ruhwald M, et al. Diagnostic accuracy of chest X-ray interpretation for tuberculosis by three artificial intelligence-based software in a screening usecase: an individual patient meta-analysis of global data. medRxiv 2022: 2022.01. 24.22269730.
- 5. Gelaw SM, Kik SV, Ruhwald M, et al. Diagnostic accuracy of three computer-aided detection systems for detecting pulmonary tuberculosis on chest radiography when used for screening: Analysis of an international, multicenter migrants screening study. PLOS Glob Public Health **2023**; 3(7): e0000402.
- Qin ZZ, Barrett R, Del Mar Castro M, et al. Early user experience and lessons learned using ultra-portable digital X-ray with computer-aided detection (DXR-CAD) products: A qualitative study from the perspective of healthcare providers. PLoS One 2023; 18(2): e0277843.
- 7. Biewer AM, Tzelios C, Tintaya K, et al. Accuracy of digital chest x-ray analysis with artificial intelligence software as a triage and screening tool in hospitalized patients being evaluated for tuberculosis in Lima, Peru. PLOS Glob Public Health **2024**; 4(2): e0002031.
- Qin ZZ, Barrett R, Ahmed S, et al. Comparing different versions of computer-aided detection products when reading chest X-rays for tuberculosis. PLOS Digit Health 2022; 1(6): e0000067.
- 9. Kagujje M, Kerkhoff AD, Nteeni M, Dunn I, Mateyo K, Muyoyeta M. The Performance of Computer-Aided Detection Digital Chest X-ray Reading Technologies for Triage of Active Tuberculosis Among Persons With a History of Previous Tuberculosis. Clin Infect Dis **2023**; 76(3): e894-e901.
- 10. Tavaziva G, Majidulla A, Nazish A, et al. Diagnostic accuracy of a commercially available, deep learning-based chest X-ray interpretation software for detecting culture-confirmed pulmonary tuberculosis. Int J Infect Dis **2022**; 122: 15-20.
- 11. Reeve BW, Ndlangalavu G, Mishra H, et al. Point-of-care C-reactive protein and Xpert MTB/RIF Ultra for tuberculosis screening and diagnosis in unselected antiretroviral therapy initiators: a prospective diagnostic accuracy study. medRxiv **2023**.
- 12. Calderwood CJ, Reeve BW, Mann T, et al. Clinical utility of C-reactive protein-based triage for presumptive pulmonary tuberculosis in South African adults. Journal of Infection **2023**; 86(1): 24-32.
- 13. Lawn SD, Kerkhoff AD, Vogt M, Wood R. Diagnostic and prognostic value of serum Creactive protein for screening for HIV-associated tuberculosis. The International journal of tuberculosis and lung disease **2013**; 17(5): 636-43.

- Derendinger B, Mochizuki TK, Marcelo D, et al. C-reactive protein-based tuberculosis triage testing: a multi-country diagnostic accuracy study. medRxiv 2024: 2024.04.23.24305228.
- 15. Sutherland JS, van der Spuy G, Gindeh A, et al. Diagnostic accuracy of the Cepheid 3gene host response fingerstick blood test in a prospective, multi-site study: interim results. Clinical Infectious Diseases **2022**; 74(12): 2136-41.
- 16. Gupta-Wright A, Ha H, Abdulgadar S, et al. Evaluation of the Xpert MTB Host Response assay for the triage of patients with presumed pulmonary tuberculosis: a prospective diagnostic accuracy study in Viet Nam, India, the Philippines, Uganda, and South Africa. Lancet Glob Health **2024**; 12(2): e226-e34.
- 17. Worodria W, Castro R, Kik SV, et al. An independent, multi-country head-to-head accuracy comparison of automated chest x-ray algorithms for the triage of pulmonary tuberculosis. medRxiv **2024**: 2024.06.19.24309061.
- 18. Organization WH. Module 2: Screening WHO Operational Handbook on Tuberculosis Systematic Screening for Tuberculosis Disease. **2021**.
- 19. Cohen JF, Korevaar DA, Altman DG, et al. STARD 2015 guidelines for reporting diagnostic accuracy studies: explanation and elaboration. BMJ Open **2016**; 6(11): e012799.
- 20. Bashir S, Kik SV, Ruhwald M, et al. Economic analysis of different throughput scenarios and implementation strategies of computer-aided detection software as a screening and triage test for pulmonary TB. PLoS One **2022**; 17(12): e0277393.
- 21. MacPherson P, Webb EL, Kamchedzera W, et al. Computer-aided X-ray screening for tuberculosis and HIV testing among adults with cough in Malawi (the PROSPECT study): A randomised trial and cost-effectiveness analysis. PLoS Med **2021**; 18(9): e1003752.
- 22. Brümmer LE, Thompson RR, Malhotra A, et al. Cost effectiveness of low-complexity screening tests in community-based case-finding for tuberculosis. Clin Infect Dis **2023**.
- 23. Murray M, Cattamanchi A, Denkinger C, Van't Hoog A, Pai M, Dowdy D. Costeffectiveness of triage testing for facility-based systematic screening of tuberculosis among Ugandan adults. BMJ Glob Health **2016**; 1(2): e000064.